Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT01406717

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
Sun Pharmaceutical Industries Limited (from the registry)
Registry
  • NCT NCT01406717
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01406717. Randomized; quadruple masking; primary purpose treatment. Start 2013-03-01 (registry gives no type); primary completion 2015-11-04 (actual). Results posted on 2019-11-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
SPIL1033
Intervention (Drug)
Placebo
Lead sponsor
Sun Pharmaceutical Industries Limited (class: industry)

Record details

Record id
cardio:ct-nct01406717
Content hash
a1f115675661cd9935bdd1f12e892267a08c8b07894eae2c3e7662546df7f696